

# Centrexion Present Updates on Advancing a Novel Analgesic Pipeline at 17th Annual Pain Summit

*SMI REPORTS: Chief Medical Officer, Randall Stevens, to present at SMI's 17th annual Pain Therapeutics conference in London*

LONDON, ENGLAND, UNITED KINGDOM, February 15, 2017

[/EINPresswire.com/](http://EINPresswire.com/) -- Stemming from insufficient efficacy and substantial risks in opioid dependency, the current set of analgesics available to patients have been inadequate to manage chronic pain, creating a growing need towards new drug discovery.

Following on from this, the established [Pain Therapeutics](#) conference will once again gather an audience of scientific pioneers and industry specialists to discuss new innovations when it returns to Central London this May for the 17th annual summit.

With a focus on advancing a novel analgesic pipeline, SMI Group are delighted to welcome the expertise of Randall Stevens, Chief Medical Officer from Centrexion Therapeutics onto the agenda for 2017. Randall Stevens has extensive experience of more than 25 years in pharmaceutical medicine and has played an integral role in bringing a total of five drugs to market.



A very informative and interactive conference”

*Past Attendee Testimonial*

His [keynote address](#) will delve deeper into; the development of novel, non-opioid analgesics which match the safety and efficacy requirements of indications and populations, the utility of Big Data analytics in identifying indications for novel analgesics; and draw from case study insight of CNTX-4975 development in Morton's Neuroma and Knee Osteoarthritis

Other notable speakers on the panel at Pain Therapeutics 2017 include:

Dr Stephen Doberstein, Senior Vice President and Chief Scientific Officer, Nektar Pharmaceuticals



The poster for the 17th Annual Show... Pain Therapeutics, held at the Copthorne Tara Hotel in London, UK, from May 22-23, 2017. The poster features a dark blue background with several anatomical illustrations of human joints and the spine, some highlighted in red and purple. The text is white and light blue. At the bottom, the website [www.pain-therapeutics.co.uk](http://www.pain-therapeutics.co.uk) and the SMI logo are displayed.

Dr Joseph W. Stauffer, Chief Medical Officer, Cara Therapeutics Inc  
Dr Iain Chessell, Head of Neuroscience, AstraZeneca  
Prof Theo Meert, Head of Global Government Grant Office, Janssen Pharmaceutica NV  
Dr Steven Kamerling, Therapeutic Area Head for Pain, Inflammation and Oncology, Zoetis  
Dr Richard Butt, Chief Executive Officer, Apollo Therapeutics  
Dr Narender Gavva, Scientific Director, Amgen  
Dr Thomas Christoph, Head of Pharmacology and Biomarker Development, Grunenthal GmbH  
Dr Ian Bell, Principal Scientist, MSD-USA  
Prof Anthony Jones, Professor of Neuro-Rheumatology, University of Manchester

Further information including a full speaker line-up is available at: [www.pain-therapeutics.co.uk](http://www.pain-therapeutics.co.uk)

Pain Therapeutics 2017  
22nd & 23rd May  
Cophthorne Tara Hotel, London, UK  
<http://www.pain-therapeutics.co.uk>

--end --

Contact Information:

For media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: [tarri@smi-online.co.uk](mailto:tarri@smi-online.co.uk)

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Teri Arri  
SMi Group  
2078276000  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.